Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), triggers rapid but largely reversible shifts in the gut microbiome of obese mice, according to a study published in the journal Microbiology Spectrum. Researchers found that while the drug alters bacterial community structure during active treatment, these changes largely normalize within seven days of discontinuing the medication.
Microbial Dynamics During Liraglutide Intervention
The study, which monitored male C57BL/6J diet-induced obese mice, tracked gut bacterial changes across a 21-day period. Investigators established three groups: a high-fat diet group receiving daily liraglutide injections (HFL), a high-fat control group (HFC), and a low-fat control group (LFC). By day 14 of the study, the HFL group showed a distinct separation in bacterial community structure compared to both baseline readings and the control groups, according to non-metric multidimensional scaling (NMDS) analysis.
The intervention specifically favored lactic acid-producing bacteria while suppressing taxa associated with protein and carbohydrate fermentation. Nine amplicon sequence variants (ASVs) linked to Lactobacillus gasseri, L. paragasseri, L. johnsonii, and Leptogranulimonas caecicola increased significantly during treatment. Conversely, 12 ASVs related to genera such as Romboutsia, Faecalicatena, and Oscillibacter declined from 11.49% to 2.61% of the community composition.
Did you know?
While the study observed significant microbial shifts, researchers did not determine whether these changes were beneficial or harmful to the mice’s overall gut health.
Reversibility and Weight Loss Trends
Weight loss in the HFL mice was immediate, with significant differences from the HFC control group appearing by the fourth day of injections. Once the daily liraglutide administration ceased on day 14, the mice experienced a gradual rebound in body weight through day 21, though they remained lighter than the high-fat control group, as noted in the study findings.
The gut microbiome followed a similar pattern of partial recovery. By day 21, seven days after the final dose, the bacterial community structure of the HFL mice converged back toward the baseline structure and the HFC control group. While Shannon diversity showed only partial recovery, Chao1 species richness returned to baseline levels. However, the study noted that Bacteroidales-related sequences remained reduced even after the week-long washout period.
Future Research Requirements
The current findings are limited to male mice and cannot be generalized to human patients. Because the study did not analyze food intake due to the mice shredding their feed, or measure direct metabolic markers like bile acids and mucin, the mechanisms behind these microbial shifts remain unidentified. Further investigation is required to determine if these bacterial changes have clinical relevance in humans or if they persist over longer treatment durations.
Frequently Asked Questions
- Do gut microbiome changes from GLP-1 drugs last forever?
The study found that in mice, the bacterial changes were largely reversible within a seven-day washout period after drug cessation. - Did the study prove that liraglutide changes human gut bacteria?
No. This study was conducted exclusively on male mice, and researchers emphasized that these findings cannot be directly applied to human cohorts without further clinical trials. - What specific bacteria were affected by the drug?
Liraglutide increased lactic acid-producing taxa, such as Lactobacillus species, while reducing fermentative taxa like Romboutsia and Oscillibacter.
Are you interested in the latest developments in metabolic health research? Subscribe to our newsletter for updates on how new treatments impact the human gut microbiome.
Related reading